CATHERINE FURLANI: Open Payments
NPI 1770631483 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$615 in 30 payments from 22 companies in 2025. Trend: 2023 $501 · 2024 $854 · 2025 $615
Food & beverage: $615
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 4 | $104 |
| Merck Sharp & Dohme LLC | 2 | $52 |
| Novartis Pharmaceuticals Corporation | 2 | $46 |
| Gilead Sciences, Inc. | 2 | $35 |
| Celgene Corporation | 2 | $32 |
| TerSera Therapeutics LLC | 2 | $31 |
| Alexion Pharmaceuticals, Inc. | 1 | $30 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
Products named: KEYTRUDA, DATROWAY, Trodelvy, REBLOZYL, Enhertu, ULTOMIRIS, PLUVICTO, clonoSEQ.
Industry payments across NC — which companies pay providers there.
